131056Feasibility of developing a novel biomarker signature as an innovative diagnostic for tuberculosis (TB)ClosedFeasibility StudiesInnovate UKThere were an estimated 8.8 million new cases of TB in 2010 and an estimated 1.4 million deaths, making this disease one of the world's biggest infectious killers. It is estimated that 1/3 of the global population is infected with latent disease. Disease transmission occurs primarily via droplets from coughing and sneezing. Early diagnosis and treatment of infective cases is key to preventing the spread of TB. ProteinLogic have established a unique protein ‘signature’ which can discriminate infectious cases from latent carriers of the disease. To become commercially competitive this signature requires further validation. This project aims to identify additional markers which can contribute to the acceptability of the test. This project will enable ProteinLogic to refine the test & check feasibility on clinical samples as a critical step towards the goal of introducing a test that could save millions of lives.